Technical Information

  • CAS no.: 260141-27-2

  • Type: API

  • Usage: Gastroesophageal reflux disease (GERD)

  • Technical description
    Vonoprazan Fumarate is the fumarate salt form of vonoprazan, a pyrrole derivative and reversible potassium-competitive acid blocker (P-CAB), with potential antacid activity. Upon administration, vonoprazan specifically and competitively binds to the gastric hydrogen-potassium ATPase (H+/K+ ATPase) proton pump at or, more likely, near its potassium ion (K+) binding site and sterically inhibits K+ binding. This blocks the activation of the H+/K+ ATPase by K+, inhibits the proton pump and prevents gastric acid secretion, thereby lowering gastric acid levels.

  • IUPAC name: (E)-but-2-enedioic acid;1-[5-(2-fluorophenyl)-1-pyridin-3-ylsulfonylpyrrol-3-yl]-N-methylmethanamine.

  • Molecular formula: C21H20FN3O6S

  • Molecular Weight: 461.5 g/mol

  • Class: Vonoprazan fumarate belongs to the pharmacological class of P-CABs (Potassium-Competitive Acid Blockers).

  • Synonyms: TAK-438, TAK 438, TAK-438 monofumarate.

All products

FOR ANY INFORMATION,
CONTACT US